WhaleCreep

Which hedge funds own CERE1EUR? CEREVEL THERAPEUTICS HLDNG I, Q2 2026 13F holders

0 tracked hedge funds disclosed a position in CERE1EUR (CEREVEL THERAPEUTICS HLDNG I) in their Q2 2026 13F filings, worth $0 in total.

0
Holders
0
New this quarter
0
Exited this quarter
$0
Combined value
–
Share of managers holding

Holders, Q2 2026

0 rows

Ownership over time

By quarter
QuarterHoldersManagers filingShare holdingCombined value
Q3 20240730.0%$0
Q2 20247739.6%$292m
Q1 20247739.6%$307m
Q4 20237739.6%$114m
Q3 20233734.1%$26.2m
Q2 20233734.1%$63.4m
Q1 20233734.1%$35.6m
Q4 20223734.1%$60.9m
Q3 20224745.4%$81.1m
Q2 20223744.1%$44.1m
Q1 20223744.1%$72.4m
Q4 20212742.7%$69.6m
Q3 20213714.2%$102m
Q2 20215717.0%$139m
Q1 20214705.7%$63.7m
Q4 20203714.2%$67.5m

Who discovered CERE1EUR first?

Earliest meaningful positions among the 13 tracked managers seen opening CERE1EUR since Q4 2020.

3 rows
Melqart Asset Management (UK) LtdQ4 20231.0%4.2%3Exited by Q3 2024−3.6%
Soros Fund ManagementQ1 20241.9%2.0%2Exited by Q3 2024−3.3%
Pentwater Capital Management LPQ4 20230.9%1.7%3Exited by Q3 2024−3.6%

Stock since is the split-adjusted change in the quarter-end price, excluding dividends, from the first reported quarter: the price the 13F filings themselves imply (value ÷ shares), blank across any gap that cannot be accounted for. It describes the stock, not the return any manager earned.